Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)

Clinical Trial ID NCT01070316

Rank	Title	Journal	Year	PubWeight™‹?›
1	New avenues for anti-epileptic drug discovery and development.	Nat Rev Drug Discov	2013	1.63
2	Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma.	Neurology	2013	1.33
3	Tuberous sclerosis complex: neurological, renal and pulmonary manifestations.	Neuropediatrics	2011	1.27
4	mTOR Inhibitors in Tuberous Sclerosis Complex.	Curr Neuropharmacol	2012	1.09
5	Is mTOR inhibition a systemic treatment for tuberous sclerosis?	Ital J Pediatr	2013	1.04
6	Tuberous Sclerosis: A New Frontier in Targeted Treatment of Autism.	Neurotherapeutics	2015	0.87
7	Optimal management of seizures associated with tuberous sclerosis complex: current and emerging options.	Neuropsychiatr Dis Treat	2014	0.83
8	Gene expression profiling of a hypoxic seizure model of epilepsy suggests a role for mTOR and Wnt signaling in epileptogenesis.	PLoS One	2013	0.82
9	The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial.	Trials	2016	0.75